cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer
cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer
复制标题
DOI：
10.1016/j.biomaterials.2012.06.008
复制
发表时间：
2012-10-01
期刊：
影响因子：
14
通讯作者：
Duan, Yourong
中科院分区：
文献类型：
--
作者：
Liu, Peifeng;Qin, Liubin;Duan, Yourong
Cyclic peptide (arginine-glycine-aspartic-glutamic-valine acid, cRGD)-modified monomethoxy (polyethylene glycol)-poly (D,L-lactide-co-glycolide)-poly (L-lysine) nanoparticles (mPEG-PLGA-PLL-cRGD NPs) with antitumor drug Mitoxantrone (DHAQ) or fluorescence agent Rhodamine B (Rb) encapsulated in their interior were prepared. The remarkable features of the mPEG-PLGA-PLL-cRGD NPs are the effective improvement for the cytotoxicity and uptake of the cell in vitro, and the significant enhancement of delivery ability for DHAQor Rb in vivo. As a consequence, an excellent therapeutic efficiency for cancer is obtained, demonstrating the mPEG-PLGA-PLL-cRGD NPs play a key role in enhancing cancer therapeutic efficiency. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
